Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

Rhea-AI Summary

Prelude Therapeutics, a clinical-stage precision oncology company, announced its participation in the Barclays Global Healthcare Conference in Miami from March 14 to 16, 2023. On March 16 at 9:30 a.m. ET, CEO Kris Vaddi and CMO Jane Huang will engage in a fireside chat. One-on-one meetings are scheduled for March 15 and 16.

Prelude focuses on developing innovative drug candidates targeting critical cancer pathways, with a pipeline featuring four candidates: PRT1419, PRT2527, PRT3645, and PRT3789.

News Market Reaction – PRLD

+4.77%

+4.77% Session move

In the trading session that priced this news, PRLD gained 4.77%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WILMINGTON, Del., March 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Barclays Global Healthcare Conference in Miami, March 14 to 16, 2023.

On March 16, at 9:30 a.m. ET, Kris Vaddi, Ph.D., CEO of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat, hosted by Barclays. The company will host one-on-one meetings on March 15 and 16.

About Prelude

Prelude is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Prelude’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a brain penetrant CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

For more information, visit our website and follow us on LinkedIn and Twitter.

Investor Contact:
Lindsey Trickett
Vice President, Investor Relations
240.543.7970
ltrickett@preludetx.com

Media Contact:
Helen Shik
Shik Communications
617.510.4373
Helen@ShikCommunications.com

 

FAQ

What is Prelude Therapeutics participating in on March 14-16, 2023?

Prelude Therapeutics will participate in the Barclays Global Healthcare Conference in Miami.

When will Prelude's CEO and CMO have their fireside chat?

The fireside chat with Prelude's CEO and CMO will take place on March 16, 2023, at 9:30 a.m. ET.

What is the focus of Prelude Therapeutics?

Prelude Therapeutics focuses on developing innovative drug candidates targeting critical pathways in cancer treatment.

What are the main drug candidates in Prelude's pipeline?

Prelude's pipeline includes PRT1419, PRT2527, PRT3645, and PRT3789.

How can I find more information about Prelude Therapeutics?

More information can be found on Prelude Therapeutics' official website and their social media channels.